95 related articles for article (PubMed ID: 17923408)
1. Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer.
Martin M; Mackey J; Vogel C
Breast; 2007 Dec; 16 Suppl 2():S127-31. PubMed ID: 17923408
[TBL] [Abstract][Full Text] [Related]
2. Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials.
Estévez LG; Muñoz M; Alvarez I; Fernández Y; García-Mata J; Ruiz-Borrego M; Tusquets I; Seguí MA; Rodríguez-Lescure A; Adrover E; Lluch A
Cancer Treat Rev; 2007 Aug; 33(5):474-83. PubMed ID: 17561350
[TBL] [Abstract][Full Text] [Related]
3. Taxanes in the adjuvant treatment of early breast cancer, emerging consensus and unanswered questions.
Tang SC
Cancer Invest; 2009 Jun; 27(5):489-95. PubMed ID: 19479486
[TBL] [Abstract][Full Text] [Related]
4. [Adjuvant chemotherapy in hormone-receptor positive HER2-negative early breast cancer].
Lopez M; Di Lauro L; Viola G; Foggi P; Conti F; Corsetti S; Sergi D; Botti C; Di Filippo F; Vici P
Clin Ter; 2009; 160(6):481-8. PubMed ID: 20198292
[TBL] [Abstract][Full Text] [Related]
5. [The role of taxanes in breast cancer chemotherapy: what's new 15 years after?].
Herceg D; Vrbanec D
Lijec Vjesn; 2009; 131(5-6):133-41. PubMed ID: 19642533
[TBL] [Abstract][Full Text] [Related]
6. Taxanes in the adjuvant treatment of node-negative breast cancer patients.
Ozdemir N; Aksoy S; Zengin N; Altundag K
J BUON; 2012; 17(1):27-32. PubMed ID: 22517689
[TBL] [Abstract][Full Text] [Related]
7. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
[TBL] [Abstract][Full Text] [Related]
8. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
9. First-line chemotherapy for HER-2 negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment.
Morabito A; Piccirillo MC; Monaco K; Pacilio C; Nuzzo F; Chiodini P; Gallo C; de Matteis A; Perrone F;
Oncologist; 2007 Nov; 12(11):1288-98. PubMed ID: 18055848
[TBL] [Abstract][Full Text] [Related]
10. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment.
Vici P; Viola G; Rossi S; Botti C; Vitucci C; Sergi D; Ferranti FR; Saracca E; Di Lauro L; Corsetti S; Foggi P; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):453-6. PubMed ID: 19169608
[TBL] [Abstract][Full Text] [Related]
11. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients.
Bria E; Nistico C; Cuppone F; Carlini P; Ciccarese M; Milella M; Natoli G; Terzoli E; Cognetti F; Giannarelli D
Cancer; 2006 Jun; 106(11):2337-44. PubMed ID: 16649217
[TBL] [Abstract][Full Text] [Related]
12. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
Moreno-Aspitia A; Perez EA
Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
14. Advances in adjuvant chemotherapy for breast cancer: the role of taxanes.
Kaklamani VG; Gradishar WJ
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S107-18. PubMed ID: 19795584
[TBL] [Abstract][Full Text] [Related]
15. Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials.
Cuppone F; Bria E; Carlini P; Milella M; Felici A; Sperduti I; Nisticò C; Terzoli E; Cognetti F; Giannarelli D
Cancer; 2008 Jul; 113(2):238-46. PubMed ID: 18470908
[TBL] [Abstract][Full Text] [Related]
16. Current status of the taxanes as adjuvant therapy for breast cancer.
Hudis C; McArthur H; Dang C
Breast; 2007 Dec; 16 Suppl 2():S132-5. PubMed ID: 17723302
[TBL] [Abstract][Full Text] [Related]
17. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
18. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
Piccart-Gebhart MJ; Burzykowski T; Buyse M; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
J Clin Oncol; 2008 Apr; 26(12):1980-6. PubMed ID: 18421049
[TBL] [Abstract][Full Text] [Related]
19. Current status of taxanes as adjuvant therapy for early-stage breast cancer.
Wolff AC
Int J Fertil Womens Med; 2005; 50(5 Pt 1):227-9. PubMed ID: 16468473
[TBL] [Abstract][Full Text] [Related]
20. The role of HER2 in metastatic breast cancer treated with a combination of taxanes and cisplatin.
Hsu HC; Chang HK; Lin YC; Hseu S; Chen JS; Yang TS; Wang HM; Shen WC
Chang Gung Med J; 2009; 32(1):33-41. PubMed ID: 19292937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
